γδ T cells contribute to the front line of lymphoid antitumor surveillance and bridge the gap
between innate and adaptive immunity. They can be readily expanded to high numbers in …

Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

BACKGROUND: There is no published overview of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …

Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling
transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially …

Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …

Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …

With the advent of immunotherapy as an integral component of multidisciplinary solid tumor
treatment, we are confronted by an unfamiliar and novel pattern of radiographic responses …

Overexpression of the epidermal growth factor receptor (EGFR) has been linked to several
human cancers, including esophageal cancer, pancreatic cancer, anal cancer, breast …

Among γδT cells, the Vδ1 subset, resident in epithelial tissues, is implied in the defense
against viruses, fungi, and certain hematological malignancies, while the circulating Vδ2 …

Background: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor
receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer …